OPEN ACCESS Freely available online

Journal of Pharmacological Reports

Commentary

Adverse Effects of Immunopharmacology and Drug-Induced Immune Reactions

Hatry Parker*

Department of Pharmacy, University of Tasmania, Hobart, Australia

ABOUT THE STUDY

Immunopharmacology, the study of how drugs interact with the immune system, has revolutionized medicine, offering solutions to a myriad of health conditions. However, alongside the benefits, this field also presents a range of adverse effects and drug-induced immune reactions that warrant careful consideration.

One of the primary concerns in immunopharmacology is the risk of hypersensitivity reactions. These reactions occur when the immune system perceives a drug as a threat, triggering an exaggerated response [1]. Hypersensitivity reactions are categorized into four types, each presenting distinct mechanisms and manifestations. Type I hypersensitivity reactions, known as immediate hypersensitivity, involve the release of histamine and other inflammatory mediators from mast cells and basophils [2]. Symptoms can range from mild itching and hives to severe anaphylaxis, a life-threatening condition characterized by difficulty breathing, a drop in blood pressure, and potentially, loss of consciousness.

Type II hypersensitivity reactions involve the activation of complement proteins and antibodies that target the body's own cells, leading to cell destruction [3]. For instance, drugs like penicillin can induce autoimmune hemolytic anemia by triggering the destruction of red blood cells.

Type III hypersensitivity reactions result from the formation of immune complexes between drugs and antibodies [4], leading to inflammation and tissue damage. This can manifest as serum sickness, characterized by fever, rash, joint pain, and in severe cases, organ damage.

Type IV hypersensitivity reactions, also known as delayed-type hypersensitivity, are mediated by T cells and occur 48-72 hours after exposure to the drug [5]. Contact dermatitis caused by topical medications like neomycin or systemic reactions to drugs like certain antibiotics exemplify this type of reaction.

Another significant concern in immunopharmacology is drug-induced immunosuppression or immunodeficiency [6]. Certain medications, particularly those used in chemotherapy or to prevent organ rejection after transplantation, can suppress the immune system, leaving individuals susceptible to infections. This vulnerability underscores the delicate balance between therapeutic effects and compromising the body's ability to defend against pathogens.

Furthermore, some drugs can trigger autoimmune disorders by disrupting immune tolerance mechanisms [7]. For instance, medications like checkpoint inhibitors used in cancer treatment can lead to immune-related adverse events, where the immune system mistakenly attacks healthy tissues, resulting in conditions like autoimmune thyroiditis or colitis.

Moreover, Drug-Induced Hypersensitivity Syndrome (DIHS), also known as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), is a severe reaction characterized by fever, rash, and multi-organ involvement. This syndrome typically occurs weeks to months after drug exposure and can be life-threatening if not promptly recognized and managed [8].

In recent years, our understanding of immunopharmacology has expanded, leading to the development of targeted therapies like monoclonal antibodies. While these therapies offer precise targeting and reduced systemic side effects, they can still elicit immune-related adverse effects, such as cytokine release syndrome or infusion reactions [9].

Efforts to mitigate these adverse effects of immunopharmacology involve rigorous preclinical testing, monitoring during clinical trials, and post-marketing surveillance [10].

Identifying individuals at higher risk of adverse reactions through genetic testing or prior medical history can aid in personalized medicine approaches to minimize risks.

While immunopharmacology has substantially advanced medical treatments, the potential for adverse effects and drug-induced immune reactions remains a critical consideration. Understanding the mechanisms behind these reactions and implementing strategies to predict, prevent, and manage them is crucial for ensuring the safe and effective use of immunopharmacological agents in clinical practice.

Correspondence to: Hatry Parker, Department of Pharmacy, University of Tasmania, Hobart, Australia, E-mail: hatryphen@gmail.com

Received: 03-Nov-2023, Manuscript No. JPR-23-28871; **Editor assigned:** 07-Nov-2023, PreQC No. JPR-23-28871 (PQ); **Reviewed:** 22-Nov-2023, QC No. JPR-23-28871; **Revised:** 29-Nov-2023, Manuscript No. JPR-23-28871 (R); **Published:** 06-Dec-2023, DOI: 10.35248/jpr.23.7.195

Citation: Parker H (2023) Adverse Effects of Immunopharmacology and Drug-Induced Immune Reactions. J Pharma Reports. 7:195.

REFERENCES

1. Kroenke K, Karlie M, Karaj G, Peradzynska J, Krauze A, Kulus M. Risk factors for local complications in children with community-acquired pneumonia. Clin Respir J 2018;12: 253-61.
2. Palma DM, Giuliano S, Cracchiolo AN, Falcone M, Ceccarelli G, Tetamo R, et al. Clinical features and outcome of patients with descending necrotizing mediastinitis: prospective analysis of 34 cases. Infection.2016;44:77-84.
3. Mohapatra MM, Rajaram M, Mallick A. Clinical, radiological and bacteriological profile of lung abscess: An observational hospital based study. Open Access Mace J Med Sci. 2018;6:1642-6.
4. Schweigert M, Dubecz A, Stadlhuber RJ, Stein HJ. Modern history of surgical management of lung abscess: from Harold Neuhof to current concepts. Ann Thorac Surg. 2011;92:2293-7.
5. Monteiro R, Alfaro TM, Correia L, Simoa A, Carvalho A, Costa JN. Lung abscess and thoracic empyema: retrospective analysis in an internal medicine department. Acta Med Port. 2011; 24 Suppl 2: 229-40.
6. Razafimanjato NNM, Ralaizafindraibe TH, Ramarolahy AR, Rajaonera TA, Rakotovao HJL. Acute descending necrotizing mediastinitis: four years of experience at a hospital center in Madagascar. Med Santé Trop.2018;28:297-301.
7. Trzeciak P, Karolak W, Gąsior M, Zembala M. In-hospital and long-term outcomes of coronary artery bypass graft surgery in patients ≤ 45 years of age and older (from the KROK registry). Cardio Pol. 2017;75:884-92.
8. Ghazal S, Kumar A, Shrestha B, Sajid S, Malik M, Rizvi N. Risk factors predicting mortality in patients with lung abscess in a public tertiary care center in Karachi, Pakistan. JNMA J Nepal Med Assis. 2013;52:571-5.
9. Liu J, Qi C, Tao K, Zhang J, Zhang J, Xu L, et al. Sericin/dextran injectable hydrogel as an optically trackable drug delivery system for malignant melanoma treatment. ACS Appl Mater Interfaces. 2016;8(10):6411-6422.
10. Terada S, Sasaki M, Yanagihara K, Yamada H. Preparation of silk protein sericin as mitogenic factor for better mammalian cell culture. J Biosci Bioeng. 2005;100(6):667-671.